M&A - Verve Therapeutics, Inc.

Form Type: 8-K

Filing Date: 2025-07-15

Corporate Action: Acquisition

Type: Update

Accession Number: 000119312525159005

Filing Summary: Verve Therapeutics, Inc. filed this Form 8-K to report on the establishment of a retention bonus program for key employees in connection with a pending acquisition. The Company granted retention awards totaling $499,200 and $416,000 to its Chief Financial Officer, Allison Dorval, and Chief Operating Officer, Andrew Ashe, respectively. The awards are contingent upon continued employment and are scheduled to be fully paid out after 12 months following the anticipated closing date of the acquisition. The merger is part of a planned transaction with Ridgeway Acquisition Corporation and Eli Lilly and Company, supported by a Merger Agreement signed June 16, 2025. This filing serves to inform investors about the ongoing acquisition process and the associated offer made to shareholders. It emphasizes the importance of reading the related documents carefully to understand the implications of tendering shares. The document also includes forward-looking statements about the acquisition process and associated risks.